Analysis of Growth Velocity in Children with Attention-Deficit/Hyperactivity Disorder Treated for up to 12 Months with Serdexmethylphenidate/Dexmethylphenidate

OBJECTIVE: Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is approved for the treatment of patients aged ≥6 years with attention-deficit/hyperactivity disorder (ADHD). A 12-month, open-label safety study with SDX/d-MPH in children with ADHD showed that SDX/d-MPH was well tolerated and comparab...

Descripción completa

Detalles Bibliográficos
Autores principales: Childress, Ann C., Cutler, Andrew J., Patel, Maitrey, Oh, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254966/
https://www.ncbi.nlm.nih.gov/pubmed/37204277
http://dx.doi.org/10.1089/cap.2023.0012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254966/
https://www.ncbi.nlm.nih.gov/pubmed/37204277
http://dx.doi.org/10.1089/cap.2023.0012

Ejemplares similares